Cryo-Cell International, Inc. (CCEL) Stock

Understand Cryo-Cell International, Inc.: how it makes money

Cryo-Cell collects and cryogenically stores umbilical cord blood and cord tissue for families, charging an annual storage fee, and sells the PrepaCyte CB processing system to collection sites. Revenue is anchored by recurring storage fees, with product sales and public banking programs as smaller, more variable add-ons.

The business monetizes a one-time collection event with a recurring annual storage fee; every unit added to the vault compounds the next year's unavoidable revenue.

Business quality (Weak): Weak. The 78% gross margin is genuine, but a 15% operating margin and minimal absolute revenue scale mean the company cannot fund meaningful R&D or market expansion. The recurring-fee model is sound in theory but unproven at this size.

Bull case

• Low-Cost Storage Economics: A 78% gross margin means each additional cord blood or cord tissue unit stored adds very little variable cost, so the unit economics improve as the vault grows without proportional spending.

Bear case

• Overhead Eats Most Gross Profit: The operating margin of 15% leaves only a thin slice after SG&A, meaning the company handles too much fixed cost relative to its very small revenue base and cannot easily scale its way out.

Related Companies (Healthcare Services; 8 comparable companies)

• Park Dental Partners, Inc. Common Stock (PARK)
• Viemed Healthcare, Inc. (VMD)
• Basel Medical Group Ltd Ordinary Shares (BMGL)
• AirSculpt Technologies, Inc. (AIRS)
• SBC Medical Group Holdings Incorporated (SBC)
• LifeMD, Inc. (LFMD)
• Strata Critical Medical, Inc. (SRTA)
• Talkspace, Inc. (TALK)